Rivaroxaban Tablets 15mg (Xarelto® / イグザレルト錠15mg)

JPY ¥52,400

Japanese Selective Direct Factor Xa Inhibitor (Rivaroxaban 15mg). Oral tablet for prevention of stroke in non-valvular atrial fibrillation and treatment/prevention of venous thromboembolism. 100 tablets [10 tablets (PTP) x 10]. Mfd. by Bayer Yakuhin, Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥48,208
10 - 19 12% JPY ¥46,112
20 + 18% JPY ¥42,968
SKU: XAR-15-TAB Category:

Description

Product Overview / 商品概要

Xarelto Tablets 15mg (イグザレルト錠15mg)
Generic: Rivaroxaban / リバーロキサバン
Therapeutic Category: Selective Direct Factor Xa Inhibitor / 選択的直接作用型第Ⅹa因子阻害剤
Manufactured by: Bayer Yakuhin, Ltd. / バイエル薬品株式会社

Composition & Specification / 組成・規格

Active Ingredient: Rivaroxaban 15mg per tablet / 1錠中リバーロキサバン15mg含有
Additives: Microcrystalline cellulose, Croscarmellose sodium, Hypromellose, Lactose hydrate, Magnesium stearate, Sodium lauryl sulfate, Iron sesquioxide, Macrogol 4000, Titanium oxide / 結晶セルロース、クロスカルメロースナトリウム、ヒプロメロース、乳糖水和物、ステアリン酸マグネシウム、ラウリル硫酸ナトリウム、三二酸化鉄、マクロゴール4000、酸化チタン
Appearance: Film-coated tablet; red; diameter 6mm; thickness 2.8mm; weight 87.5mg
外観: 剤形: フィルムコーティング錠、色調: 赤色、直径: 6mm、厚さ: 2.8mm、質量: 87.5mg

Indications / 効能効果

EN: Adults: Prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation; Treatment and prevention of recurrence of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Pediatrics: Treatment and prevention of recurrence of venous thromboembolism; Prevention of thromboembolism after Fontan surgery.
JA: 【成人】非弁膜症性心房細動患者における虚血性脳卒中及び全身性塞栓症の発症抑制、静脈血栓塞栓症(深部静脈血栓症及び肺血栓塞栓症)の治療及び再発抑制【小児】静脈血栓塞栓症の治療及び再発抑制、Fontan手術施行後における血栓・塞栓形成の抑制

Dosage and Administration / 用法用量

EN: Prevention of ischemic stroke and systemic embolism in non-valvular atrial fibrillation (adults): 15mg orally once daily after meals; reduce to 10mg once daily in patients with renal impairment. Treatment and prevention of recurrence of VTE (adults): 15mg twice daily after meals for the first 3 weeks following DVT or PE onset, then 15mg once daily after meals. Treatment and prevention of recurrence of VTE (pediatrics, body weight ≥30kg): 15mg once daily after meals.
JA: 【非弁膜症性心房細動患者における虚血性脳卒中及び全身性塞栓症の発症抑制】通常、成人にはリバーロキサバンとして15mgを1日1回食後に経口投与する。なお、腎障害のある患者に対しては、腎機能の程度に応じて10mg1日1回に減量する。【静脈血栓塞栓症の治療及び再発抑制(成人)】通常、成人には深部静脈血栓症又は肺血栓塞栓症発症後の初期3週間はリバーロキサバンとして15mgを1日2回食後に経口投与し、その後は15mgを1日1回食後に経口投与する。【静脈血栓塞栓症の治療及び再発抑制(小児)】通常、体重30kg以上の小児にはリバーロキサバンとして15mgを1日1回食後に経口投与する。

Contraindications / 禁忌

EN: History of hypersensitivity to the product components; patients with clinically significant bleeding (intracranial hemorrhage, gastrointestinal bleeding, etc.); hepatic disease with coagulopathy; moderate or severe hepatic impairment (Child-Pugh Class B or C); pregnant women or women who may be pregnant; patients receiving ritonavir-containing preparations, darunavir, or fosamprenavir; patients receiving cobicistat-containing preparations; patients receiving oral or injectable itraconazole, posaconazole, voriconazole, miconazole, or ketoconazole; patients receiving ensitrelvir; patients receiving lonafarnib; patients with acute bacterial endocarditis; patients with severe renal impairment (adults: creatinine clearance <30mL/min; pediatrics: eGFR <30mL/min/1.73m²).
JA: 本剤の成分に対し過敏症の既往歴のある患者、出血している患者(頭蓋内出血・消化管出血等の臨床的に重大な出血)、凝固障害を伴う肝疾患の患者、中等度以上の肝障害(Child-Pugh分類B又はCに相当)のある患者、妊婦又は妊娠している可能性のある女性、リトナビルを含有する製剤・ダルナビル・ホスアンプレナビルを投与中の患者、コビシスタットを含有する製剤を投与中の患者、イトラコナゾール・ポサコナゾール・ボリコナゾール・ミコナゾール・ケトコナゾールの経口又は注射剤を投与中の患者、エンシトレルビルを投与中の患者、ロナファルニブを投与中の患者、急性細菌性心内膜炎の患者、重度の腎障害(成人ではクレアチニンクリアランス30mL/min未満、小児ではeGFR 30mL/min/1.73m²未満)のある患者

Regulatory Information / 規制情報

Approval No.: 22400AMX00041000
Sales Started: April 2012 / 2012年4月
Classification Code: 873339
Storage: Store at room temperature / 室温保存
Shelf Life: 36 months / 36ヵ月

Packaging / 包装

Main Package (for sale): 100 tablets [10 tablets (PTP) x 10] / 100錠[10錠(PTP)×10]
Other Available Packages (by special order): 100 tablets [10 tablets (PTP) x 10]; 500 tablets [bottle, bulk]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Rivaroxaban Tablets 15mg (Xarelto® / イグザレルト錠15mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Rivaroxaban Tablets 15mg (Xarelto®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.